

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE		
					SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	18 -20	=	0	X	\$ 9.00	\$18.00	=	\$ 0	\$
Independent , Claims	4 -3	=	1	X	\$40.00	\$80.00	=	\$ 40.00	\$
Multiple Dependent Claims Presented: <u> X </u> Yes <u> </u> No					\$135.00	\$270.00	=	\$ 135.00	\$
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE			\$ 355.00	\$ 710
					TOTAL FEE			\$ 530.00	\$

X A check in the amount of \$ 530.00 to cover the filing fee.

 Please charge Deposit Account No. in the amount of
\$.

X The Commissioner is hereby authorized to charge any additional fees
which may be required in connection with the following or credit any
over-payment to Account No. 03-3125:

X Filing fees under 37 C.F.R. §1.16.

X Patent application processing fees under 37 C.F.R. §1.17.

 The issue fee set in 37 C.F.R. §1.18 at or before mailing of the
Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

 Three copies of this sheet are enclosed.

 A certified copy of previously filed foreign application No.
 filed in on .

Applicant(s) hereby claim priority based upon this aforementioned
foreign application under 35 U.S.C. §119.

X Other (identify)

One extra set of formal drawings and an Express Mail
Certificate of Mailing bearing label number EI 900 852 073 US.

Respectfully submitted,

Janem Love

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

1185 Avenue of the Americas
New York, New York 10036
November 28, 2000

SIR:

"Express Mail" mailing label number: EJ 900 852 073 US
Date of Deposit: November 28, 2000
I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 C.F.R. §1.10 on the date indicated
above and is addressed to the Assistant Commissioner for Patents
Box Patent Application, Washington, D.C. 20231.

Printed Name: 101W 150A

Jane M. Jones

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

[illegible]

To all whom it may concern:

Be it known that **Paul B. Fisher and Dong-Chul Kang**

have invented certain new and useful improvements in

Method for Full-Length cDNA Cloning Using Degenerate Stem-Loop Annealing Primers

of which the following is a full, clear and exact description.

5

10

15

25

The human genome is estimated to contain 100,000 genes, the expressions of which define the functionality of a cell (1). Current technological advances, including large-scale DNA

sequencing, efficient library construction and manipulation and PCR-based gene expression monitoring, have resulted in the identification of more than 87,000 unique expression sequence tags (ESTs) in diverse cell types and under various physiological conditions (1). Approximately 12 % of the ESTs have significant homology with previously identified genes and the remainder require further investigation to define their identity and biological relevance (1). However, ESTs, short stretches of expressed genes, can only provide limited information as to the identity and biological role of specific genes. A more thorough analysis of the ESTs requires a determination of the full protein coding sequences for these expressed genes.

Several approaches are routinely used to obtain cDNAs containing protein-encoding sequences from ESTs. These include, library screening (2) and the PCR-based rapid amplification of cDNA ends (RACE) strategy (3). A less frequently employed scheme, exon trapping is also amenable to cDNA cloning from genomic fragments (4,5).

A number of cDNA libraries from diverse sources are commercially available. This can in specific instances reduce the burden of producing cDNA libraries that are required for screening for cDNAs. However, even with well-constructed cDNA libraries, several rounds of screening and verification are often required to obtain even a single complete cDNA (2). This process is laborious and can require months of intensive effort. What exacerbates the

10

Summary of the Invention

00224033 12800

The present invention provides a method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises: (A) admixing (i) an isolated single-stranded cDNA, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence, linked to (b) a second sequence, linked to (c) a third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, under hybridization conditions sufficient for annealing the first sequence of the first primer to the sequence at the 3' end of the single-stranded cDNA, and (iii) a polymerase; (B) incubating the mixture from step (A) under suitable conditions for DNA synthesis; and (C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which specifically binds to the single-stranded cDNA, (iii) a third primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a portion of the second sequence of the first primer, and (iv) a polymerase, under conditions suitable for a polymerase chain reaction so as to produce a double-stranded cDNA reaction product, thereby isolating the cDNA having the sequence of the complete open reading frame.

Brief Description of the Figures

Figures 1A-C: Schematic of the C-ORF procedure and the primers used in this approach. **Fig 1A.** In C-ORF, specifically designed primers anneal to the 3' end of the first strand cDNA. Extended cDNA from this primer can be amplified by PCR with a gene specific primer (GSP) and a universal anchor primer containing the annealing primer sequence. This method dispenses with rate limiting steps of conventional RACE, such as homopolymer tailing or single strand ligation. **Fig 1B.** Primers (D-SLAP, D-CLAP1 and D-CLAP2) used in the 5' C-ORF reaction. The stem-and-loop structure of these primers is designed to prevent, by steric hindrance, degenerate regions from annealing to internal sites, thereby insuring efficient extension of the gene product. D-CLAP1 contains additional GGG sequences to enhance annealing to the C-homopolymer tail generated by the TdT-like activity of reverse transcriptase (RT). **Fig 1C.** In the T-SLAP reagent, dT replaces the random sequences used for the reverse transcription reaction as a primer.

Figures 2A-2E. C-ORF cloning of the novel gene *mda-5*. **Fig 2A.** *Mda-5* C-ORF products (12 μ l nested PCR) with reverse transcription reactions at specified temperature are resolved in a 1% agarose gel containing EtBr. **Fig 2B.** C-ORF products of *mda-5* performed with different amounts of the D-SLAP reagent and the anchor primer in primary PCR for second strand cDNA synthesis. **Fig 2C.** An autoradiogram of Southern blot hybridization of C-ORF products of *mda-5*

resolved in (B) with ^{32}P -labeled nested primers. **Fig 2D.** An autoradiogram of Northern blot hybridization of RNA samples prepared from HO-1 human melanoma cells either left alone (Con) or treated with 2,000 U/ml IFN- β plus 10 ng/ml mezerein. Left panel was probed with ^{32}P -labeled *mda-5* EST (0.4 kb) previously cloned by library screening. The right panel was probed with a ^{32}P -labeled 1.8-kb *mda-5* C-ORF product. **Fig 2E.** RT-PCR analysis using sequence information derived from the *mda-5* C-ORF product. RT-PCR was performed using 2 μl of the reverse transcription reaction with the specified primer, either R2S8 or R4S8, and 12 μl of the reaction was run on the gel.

Figure 3. Applications of the C-ORF protocol for identification of the complete ORF of ISG-56, *mda-9* and *mda-5*. C-ORF products of ISG-56, *mda-9* and *mda-5* were resolved in 1 % agarose gel (lanes 3, 6 and 9). The C-ORF products are shown in comparison with the RT-PCR products of each gene using a common 3' nested primer and a 5' primer from reported gene sequence (lanes 2, 5 and 8). Nested PCR of C-ORF with only an anchor primer (lanes 4, 7 and 10) distinguishes gene specific C-ORF products from RT-PCR artifacts.

Figures 4A-4B. C-ORF protocol with the D-CLAP1 and D-CLAP2 reagents for 5' cDNA end cloning. **Fig 4A.** C-ORF products obtained using the D-CLAP1 reagent for the specified genes were separated in a 1% agarose gel. Authentic bands of the appropriate target size are marked with dots. Duration of

5

10

15

Detailed Description of the Invention

The present invention provides for a method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises: A) admixing (i) an isolated single-stranded cDNA, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence, linked to (b) a second sequence, linked to (c) a third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, under hybridization conditions sufficient for annealing the first sequence of the first primer to the sequence at the 3' end of the single-stranded cDNA, and (iii) a polymerase; B) incubating the mixture from step (A) under suitable conditions for DNA synthesis; and C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which specifically binds to the single-stranded cDNA, (iii) a third primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a portion of the second sequence of the first primer, and (iv) a polymerase under conditions suitable for a polymerase chain reaction so as to produce a double-stranded cDNA reaction product, thereby isolating the cDNA having the sequence of the complete open reading frame.

In one embodiment of the invention, the single-stranded DNA is a 5' portion of a cDNA reverse transcribed from an mRNA.

In another embodiment of the invention, the first primer has the sequence 3'-

NNNNNNNNNNNNNCAGAGCTCAAATTTGTGATCAGCTGGTCTTTCACAAATTTGAGCTC
TG-5' (D-SLAP).

5 In another embodiment of the invention, the first primer has the sequence

3'NNNNNNNNNNNGGGGAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGTAGAAT
ACATCTTGAGCTAT-5' (D-CLAP1).

10 In a further embodiment of the invention, the first primer has the sequence

3'NNNNNNNNNNNNNAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGTAGAAT
ACATCTTGAGCTAT(D-CLAP2).

15 In another embodiment of the invention, the first primer comprises an inosine nucleotide.

In a further embodiment of the invention, the loop structure is a simple loop structure, or a cloverleaf loop structure.

20

The present invention provides for a method for generating a cDNA library which comprises: A) admixing (i) a population of single-stranded cDNA molecules which were reverse transcribed with an oligo-dT sequence linked to a defined nucleotide sequence, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence linked to (b) a second sequence, linked to (c) a third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5' end of

09724028.1 2800

the first primer, which is complementary to the second sequence, under hybridization conditions sufficient for annealing the first sequence of the first primer to the sequence at the 3' end of the single-stranded cDNA, and
5 (iii) a polymerase; B) incubating the mixture from step (A) under suitable conditions for DNA synthesis by the polymerase; and C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which has the identical sequence as the
10 defined nucleotide sequence of the primer in (A) (i), (iii) a third primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a portion of the second sequence of the first primer, and (iv) a polymerase under
15 conditions suitable for a polymerase chain reaction so as to produce double-stranded cDNA reaction products thereby generating a cDNA library.

In one embodiment, the single-stranded DNA is a cDNA reverse
20 transcribed from an mRNA.

In another embodiment of the invention, the first primer has the sequence 3'-
NNNNNNNNNNNNCAGAGCTCAAATTTGTGATCAGCTGGTCTTTCACAAATTTGAGCTC
25 TG-5' (D-SLAP).

In another embodiment of the invention, the first primer has the sequence
3' NNNNNNNNNNNGGAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGTAGAAT

ACATCTTGAGCTAT-5' (D-CLAP1).

In another embodiment of the invention, the first primer has the sequence

5 3'NNNNNNNNNNNNNAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGTAGAAT
ACATCTTGAGCTAT(D-CLAP2).

In another embodiment of the invention, the first primer comprises an inosine nucleotide.

10

In another embodiment of the invention, the loop structure is a simple loop structure, or a cloverleaf loop structure.

15 The present invention provides for a kit for the generation of a complete open reading frame double-stranded cDNA of interest which comprises: (i) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence linked to (b) a second sequence, linked to (c) a third sequence which forms
20 a loop structure, linked to (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, and (ii) a second primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a
25 portion of the second sequence of the first primer.

The present invention also provides for a method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises:

094031224260

002211 2204260

(a) admixing (i) a biological sample containing mRNA, (ii) a primer which forms a stem-loop structure, comprising: (a) a poly-T sequence at the 3' end of the primer linked to (b) a first random sequence linked to (c) a second sequence which forms a loop structure linked to (d) a third sequence at the 5' end of the primer which is complementary to the first sequence, and (iii) a reverse transcriptase, under hybridization conditions sufficient for annealing the primer to the mRNA poly-A sequence; (b) incubating the mixture from step (a) under suitable conditions for reverse transcription; (c) performing a polymerase chain reaction with an aliquot of the mixture from step (b) using one gene-specific primer which is pre-defined and one primer which has a sequence identical to at least a portion of the primer sequence of element (ii), thereby isolating the cDNA having the sequence of the complete open reading frame.

In one embodiment of the invention, the primer has the sequence 3' - TTTTTCAGAGCTCAAATTTGTGATCAGCTGGTCTTTCACAAATTTGAGCTC TG-5' (T-SLAP).

In addition, the present invention is directed to a method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises: A) admixing (i) an isolated single-stranded cDNA, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence, linked to (b) a second sequence, linked to (c) a

third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, under ligation conditions sufficient for ligating the first sequence of the first primer to the sequence at the 3' end of the single-stranded cDNA, and (iii) a ligase; B) incubating the mixture from step (A) under suitable conditions for ligation; and C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which specifically binds to the single-stranded cDNA, (iii) a third primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a portion of the second sequence of the first primer, and (iv) a polymerase under conditions suitable for a polymerase chain reaction so as to produce a double-stranded cDNA reaction product, thereby isolating the cDNA having the sequence of the complete open reading frame.

The present invention provides for a method for generating a cDNA library which comprises: A) admixing (i) a population of single-stranded cDNA molecules which were reverse transcribed with an oligo-dT sequence linked to a defined nucleotide sequence, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3' end of the primer, a first random sequence linked to (b) a second sequence, linked to (c) a third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, under ligation conditions sufficient for ligation

of the first sequence of the first primer to the sequence at the 3' end of the single-stranded cDNA, and (iii) a ligase; B) incubating the mixture from step (A) under suitable conditions for DNA synthesis by the polymerase; and C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which has the identical sequence as the defined nucleotide sequence of the primer in (A)(i), (iii) a third primer which comprises (a) a fifth sequence identical to the third sequence of the first primer, linked to (b) a sixth sequence identical to a portion of the second sequence of the first primer, and (iv) a polymerase under conditions suitable for a polymerase chain reaction so as to produce double-stranded cDNA reaction products thereby generating a cDNA library.

15

The following are several applications of the present invention:

1. Cloning the 5' end of a cDNA from an EST.
2. Cloning the 3' end of a cDNA from an EST by performing C-ORF in a reverse transcription reaction.
3. Construction of a cDNA library containing a high proportion of full-length cDNAs.
4. Genomic cloning, both upstream and downstream regions of known sequences.
- 25 5. Capture nucleic acid of specific sequence for purification and diagnostic purposes.
6. Gene inactivation by inhibiting mRNA entry onto the ribosome for translation.
7. Cloning family of genes, such as kinases.

9. Chromosomal mapping.

5
10

20

25

libraries and/or the PCR-based 5' RACE approach. Screening
cDNA libraries is very labor intensive and often yields
incomplete cDNA, which necessitates the use of additional 5'
cloning methods such as 5' RACE. To reach the 5' end of a
5 cDNA two PCR-based methods have been used, 5' RACE employing
terminal deoxytransferase to prime the 3' end of the first
strand cDNA and linker ligation using RNA ligase. However,
these methods are limited in effectiveness because of the
low efficiency of the priming procedure. We describe a
10 novel way of priming the 3' end of first strand cDNA that
allows the second strand of cDNA to be synthesized
preferentially from the 3' end of the first strand of cDNA.

Degenerate stem and loop cDNA end annealing primer (D-SLAP)
15 methods were designed to preferentially anneal to the 3' end
of the first strand of cDNA. The primer consists of two
functional components: 1) a stem and a loop (stem-and-loop)
component and 2) the annealing of degenerate nucleotides.
The stem-and-loop structure sterically hinders degenerate
20 oligonucleotides from annealing to the middle of a cDNA and
promotes preferential annealing to the end of the first
strand of cDNA. Conceptually, the stem-and-loop of the D-
SLAP method should form molecular complexes at higher
temperatures preventing the binding of degenerate
25 oligonucleotides. This could occur because the longer
region of potential base pairing in the stem-and-loop region
should facilitate intramolecular annealing over degenerate
oligonucleotide binding. Alternatively, the longer region
of base pairing in the stem-and-loop and the intramolecular

annealing reaction mechanics may facilitate formation of stem-and-loop structure prior to degenerate oligonucleotide annealing.

- 5 Full-length cloning of a 5' sequence of cDNA using the D-SLAP method was performed as follows. Total RNA (2 μ g) treated with RNase-free DNase was extracted and reverse transcribed with a gene specific primer using MMLV RT (Superscript RT II from Gibco-BRL) as in the 5' RACE
10 protocol (Gibco-BRL) at 48 $^{\circ}$ C and inactivated by incubation at 85 $^{\circ}$ C for 5 minutes. After treatment with a mixture of RNase H and RNase I for 30 minutes at 37 $^{\circ}$ C, first strand cDNA was purified with GlassMax[®] (Gibco-BRL) and the second strand of cDNA was synthesized using D-SLAP method.
15 Purified first strand cDNA was mixed with 1 pmole of D-SLAP reactants and KlenTaq reaction buffer, and heated at 95 $^{\circ}$ C for 1.5 minutes and slowly cooled down to 45 $^{\circ}$ C. KlenTaq (0.25 μ l, Clontech) and dNTP (0.5 μ l of 10mM, Gibco-BRL) were added to the 45 $^{\circ}$ C equilibrated reaction mixture and
20 subsequently second strand cDNA synthesis was performed by incubation at 68 $^{\circ}$ C for 30 minutes. A PCR reaction was set up with 5 μ l of the cDNA synthesis reaction mixture, 5' anchor primer designed from the loop area of D-SLAP and a gene specific primer. Secondary PCR was performed with 0.5
25 μ l of the primary PCR product, the same 5' anchor primer (for nested PCR primers) and a nested gene specific primer.

D-SLAP second strand synthesis was applied to clone a full-length *mda-5* (melanoma differentiation associated gene-5)

003277 22042260

003347 " 2204260

cDNA. This approach reproducibly yielded an approximately
~ 2 Kb *mda-5* amplification product. The DNA fragment was
isolated and confirmed to be *mda-5* by Northern blot analysis
and sequencing. This experiment result represents proof-of-
5 practice for the D-SLAP method. One improvement of this
procedure includes using inosine nucleotide-containing
degenerate primers and incorporating a single tube second
strand synthesis and PCR amplification procedure. If
successful these modifications will significantly simplify
10 full-length cDNA cloning using the D-SLAP methodology.
Additionally, the D-SLAP method can be used to generate cDNA
libraries for second strand synthesis that contain a high
proportion of full-length cDNAs. Moreover, with
modification of the D-SLAP procedure can be used to clone
15 the 3' end of a partial cDNA by substituting oligo dT for
the degenerate primers and incorporating a reverse
transcription reaction.

The D-SLAP method can also be formatted for use as a kit for
20 the generation of full-length cDNAs. It will have wide
applicability for the efficient and rapid production of
full-length cDNAs from ESTs. In these contexts, this
approach represents a major scientific advance in gene
cloning with significant financial potential.

25 The present invention provides for novel molecular
approaches for the identification of genes and gene products
amenable for the targeted therapy of human diseases. In
addition, there is specific focus on autoimmune diseases,

cancer, cardiovascular and infectious disease states.

One purpose of the present invention is to provide novel technologies for the identification, complete open reading frame cDNA cloning and functional analysis of genes relevant to human diseases. In addition, the present invention also utilizes molecular approaches and high throughput screening procedures to identify small molecules and novel gene products that can directly intervene in disease processes.

The present invention provides for efficient production of the complete open reading frames of cDNAs from partial cDNAs and ESTs. This approach is called the Complete Open Reading Frame (C-ORF) cloning method. This method also offers the ability to generate cDNA libraries which contain a high proportion of full-length cDNAs. A modification of this method is wherein a 3' C-ORF which permits cloning of complete open reading frame cDNAs from partial internal cDNAs missing 3' regions.

This invention also provides for functional gene evaluation. This includes the efficient and stable generation of target cells containing inducible genes for direct functional analysis and the identification of down-stream target genes and biochemical pathways mediating biological responses. These methods include the use of promoters to drive inducible target genes that are more resistant to loss of gene expression after integration and vector constructs that induce tight-regulation of target gene expression.

In addition, this invention also provides for promoter generation and analysis methods which will permit the rapid identification of the promoter region of potentially important genes regulating disease states. The promoters are used as part of a small molecule screening effort, the Rapid Promoter Screening (RPS) approach, to identify potential inhibitors and activators of disease gene transcription. These small molecules will be tested for efficacy in ameliorating specific disease states.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology and recombinant DNA technology which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL press, 1986); Perbal, B., A Practical Guide to Molecular Cloning (1984); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); and Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications).

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references

unless the content clearly dictates otherwise.

As used herein "nucleic acid molecule" includes both DNA and RNA and, unless otherwise specified, includes both double-
5 stranded and single-stranded nucleic acids. Also included are hybrids such as DNA-RNA hybrids. Reference to a nucleic acid sequence can also include modified bases as long as the modification does not significantly interfere either with binding of a ligand such as a protein by the nucleic acid or
10 Watson-Crick base pairing.

A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently
15 linked) into chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. In eucaryotic cells, a stably transformed cell is generally one in which the exogenous DNA has become
20 integrated into the chromosome so that it is inherited by daughter cells through chromosome replication, or one which includes stably maintained extrachromosomal plasmids. This stability is demonstrated by the ability of the eucaryotic cell to establish cell lines or clones comprised of a
25 population of daughter cells containing the exogenous DNA.

The transformation procedure used depends upon the host to be transformed. Mammalian cells can conveniently be transformed using, for example, DEAE-dextran based

003377 2204260

procedures, calcium phosphate precipitation (Graham, F. L. and Van der Eb, A. J. (1973) Virology 52:456-467), protoplast fusion, liposome-mediated transfer, polybrene-mediated transfection and direct microinjection of the DNA into nuclei. Bacterial cells will generally be transformed using calcium chloride, either alone or in combination with other divalent cations and DMSO (Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989)). DNA can also be introduced into bacterial cells by electroporation. Methods of introducing exogenous DNA into yeast hosts typically include either the transformation of spheroplasts or transformation of intact yeast cells treated with alkali cations.

Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes (See, e.g. New England Biolabs Product Catalog). In general, about 1 μ g of plasmid or DNA sequences is cleaved by one unit of enzyme in about 20 μ l of buffer solution. Typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37° C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If

desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in
5 Enzymology 65:499-560 (1980).

Restriction cleaved fragments may be blunt ended by treating with the large fragment of *E. coli* DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates
10 (dNTPs) using incubation times of about 15 to 25 min at 20°C to 25°C in 50 mM Tris (pH 7.6) 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 5-10 μM dNTPs. The Klenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired,
15 selective repair can be performed by supplying only one of the dNTPs, or with selected dNTPs, within the limitations dictated by the nature of the sticky ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate
20 conditions with S1 nuclease or Bal-31 results in hydrolysis of any single-stranded portion.

Ligations are performed in 10-50 μl volumes under the following standard conditions and temperatures using T4 DNA
25 ligase. Ligation protocols are standard (D. Goeddel (ed.) Gene Expression Technology: Methods in Enzymology (1991)). In vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase

003374 224260

(CIP) in order to remove the 5' phosphate and prevent religation of the vector. Alternatively, re-ligation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted
5 fragments.

The Complete Open Reading Frame (C-ORF) Technology: A Simple and Efficient Approach for Obtaining the Entire Protein Coding Region of Genes

10

The ability to analyze a gene's function often requires the identification of the protein-coding region of that gene. Although a number of approaches, including library screening and rapid amplification of cDNA ends (RACE), have been used
15 extensively to identify the complete open reading frame (ORF) of specific cDNA's, these approaches can be inefficient, time consuming and costly. An approach is described, the C-ORF (complete open reading frame) technology, that results in the rapid and efficient
20 identification of protein coding regions of genes in which limited sequence information is available. This scheme was applied successfully, in the majority of cases involving only a single application, in identifying and cloning the complete ORF of genes ranging in size from 1.2 to 8 kb. The
25 C-ORF approach will prove valuable in efforts designed to define the function of a gene in situations where only expressed sequence tags (ESTs) or incomplete cDNA genetic information is available. This strategy offers promise for accelerating the pace of gene discovery and for rapidly

002277-8204260

The human genome is estimated to contain 100,000 genes, the expressions of which define the functionality of a cell (1). Current technological advances, including large-scale DNA sequencing, efficient library construction and manipulation and PCR-based gene expression monitoring, have resulted in the identification of more than 87,000 unique expression sequence tags (ESTs) in diverse cell types and under various physiological conditions (1). Approximately 12 % of the ESTs have significant homology with previously identified genes and the remainder require further investigation to define their identity and biological relevance (1). However, ESTs, short stretches of expressed genes, can only provide limited information as to the identity and biological role of specific genes. A more thorough analysis of the ESTs requires a determination of the full protein coding sequences for these expressed genes.

A number of cDNA libraries from diverse sources are commercially available. This can in specific instances

00027"2204260

reduce the burden of producing cDNA libraries that are required for screening for cDNAs. However, even with well-constructed cDNA libraries, several rounds of screening and verification are often required to obtain even a single
5 complete cDNA (2). This process is laborious and can require months of intensive effort. What exacerbates the situation is that cDNA library screening occasionally results in incomplete cDNAs lacking full protein coding information. This occurs primarily because of premature
10 termination of reverse transcription and the self-priming procedure during second strand cDNA synthesis (2, 6, 7). Additionally, obtaining cDNA of low abundance mRNA is rarely achievable unless the cDNA library is high titer and minimally amplified (2). In these contexts, the current
15 approach of cDNA library screening to obtain full protein coding sequence is often costly, laborious and inefficient.

Recent improvements in cDNA library construction can significantly increase the proportion of full-length cDNAs.
20 These approaches include trapping m⁷GTP-cap in RNA-DNA hybrid (8), ligation of oligonucleotides to de-capped mRNA with T4 RNA ligase (9) and Cap-switch cDNA Library Synthesis Kit utilizing the terminal deoxyribonucleotide transferase (TdT)-like activity of reverse transcriptase (10-12).
25 However, some of these newer protocols involve additional steps including cumbersome chemical or enzymatic reactions (8, 9). Although cDNA library screening can identify mRNA variants and provide more reliable sequence information than PCR, the construction of high-quality cDNA libraries is not

00337 2204260
routinely achievable in most research laboratories (13).
Considering the cost of cDNA library construction, clonal
redundancy, the laborious nature of the subsequent screening
approach and the cost of sequencing, improved approaches for
5 obtaining full-length cDNAs and complete open reading frames
for cDNAs are required.

PCR-based cDNA cloning methods such as RACE and variations
of this scheme have certain advantages over cDNA library
10 screening approaches (14). Since Frohman et al. (15)
introduced the RACE approach, this method has been modified
extensively (14). Fundamentally, RACE employs a single-side
specific PCR of a target cDNA synthesized by reverse
transcription with a gene specific primer. The second
15 universal primer site is provided by homopolymer-tailing
with Tdt (15,16) or by single strand anchor ligation to the
first strand cDNA with T4 RNA ligase (17,18). PCR is
performed with the gene specific primer and a universal
primer, and the products are purified and analyzed. In
20 addition to 5' cDNA end cloning and analysis, ligation of
oligonucleotide to 3' mRNAs (19) or reverse transcription
with an oligo-dT-anchor hybrid primer (15) also enables 3'
end cloning of mRNAs. The entire procedure requires two
days, which represents a significant reduction in time in
25 comparison with cDNA library screening. Moreover, the
amplification power of PCR permits the cloning of low
abundant mRNA molecules and requires relatively small
amounts (1 μ g of total RNA) of starting material (20).

0974020-1300
The application of RACE for obtaining full-length cDNAs, however, is not as simple and straightforward as the theory behind the technique suggests. Problems, such as premature termination of reverse transcription because of the secondary structure of the mRNA, is common to both RACE and cDNA library construction (6). Thermostable RT (14) or the addition of threhalose (21) permits reverse transcription at higher temperatures (~50 to 60°C) and can reduce secondary structure formation. PCR-related problems encountered using the various RACE procedures include:

1. Generation of non-specific products due to the insufficient specificity and priming of the universal primer to intragenic sites.
2. A high rate of false incorporation of bases frequently occurs using Taq polymerase, a problem which can be reduced (3-to-5-fold), but not completely eliminated, by using enzymes with proofreading activity.
3. Amplification biases often resulting in the preferential amplification of shorter products (less than 1 kb).
4. Production of artifacts by amplification of incorrect hybrid molecules resulting from template self-annealing or mispriming (13, 20).

Thus, amplification of shorter fragments than target length probably arises from premature termination of reverse

5

10

25

5

15

25

annealing primer (D-SLAP) or a degenerate clover-leaf
annealing primer (D-CLAP) which anneals to the 3' end of the
first strand cDNA provides a universal primer site for
second strand cDNA provides a universal primer site for
5 second strand cDNA synthesis and subsequent PCR. The C-ORF
protocol includes reverse transcription, second strand cDNA
synthesis and PCR amplification with nested primers and
requires RT, Taq polymerase and the D-SLAP reagent. Proof-
of-principle for the C-ORF technology has come from an
10 analysis of both known and novel gene sequences resulting in
the identification of complete open reading frames for cDNAs
ranging in size from 1.2 to 8 kb. These include the
following known genes, interferon stimulated gene-56 (ISG-
56; 1.5 kb) (27), melanoma differentiation associated gene-9
15 (mda-9; 2 kb) (28), prostate carcinoma tumor antigen gene-1
(PCTA-1; 3.5 and 6 kb) (29) and fibronectin (8 kb) (30).
Complete open reading frames for novel cDNAs identified by
C-ORF include, melanoma differentiation associated gene-5
(mda-5; 3.5 kb) (31, 32), progression elevated gene-28
20 (PEGen 28; 1.2 kb) (33), progression elevated gene-42 (PEGen
42; 1.2 kb) (33), progression suppressed gene-12 (PSGen 12;
1.2 kb) (33) and a novel gene associated with
differentiation and senescence (OLD-35; 2 kb) (34). In
addition, the C-ORF technology can also be used for
25 determining complete 3' sequence information. Using oligo
dT-SLAP in a reverse transcription reaction allowed 3' end
cloning of PCTA-1 (1 kb fragment (29), PEGen 28 (0.7 kb
fragment) (33) and OLD-35 (34). Prerequisites for the C-ORF
protocol include at least 100-bp of sequence information,

003377" 82042459

Example 1: The Complete Open Reading Frame (C-ORF)
Technology: A Simple and Efficient Approach for Obtaining
the Entire Protein Coding Region of Genes

Cell cultures: HO-1 human melanoma cells (32) were grown in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin G and 100 μ g/ml streptomycin in a 5% CO₂ 95% air humidified incubator at 37°C. Du-145, a human prostate carcinoma cell line, was cultured in RPMI supplemented with the same reagents. Cells were maintained in the logarithmic phase of growth by subculturing 1:10 approximately two times per week.

C-ORF method for 5' cDNA end cloning: C-ORF consists of three reaction steps, reverse transcription (RT), second

strand synthesis and PCR. RNA samples (2 μ g) are reverse transcribed by SuperScript RT II (RNase H minus MMLV RT, BRL) with minor modifications from the manufacturer's protocol. The modifications include the use of 5 mM DTT instead of 10 mM DTT, 2 pmole gene specific RT primer for oligo dT and inclusion of 5 U RNaseIn. The RT reaction temperature was 45°C unless specified. First strand cDNA was purified with GlassMax(BRL) after RNase H (2.2 U) plus RNase A (0.5 μ g) digestion for 30 min at 37°C (50 μ l final). A degenerate stem-and-loop annealing primer (D-SLAP or D-CLAP) was annealed in a 20 μ l mixture of 10 to 16 μ l cleaned first strand cDNA, 2 pmole annealing primer and 2 μ l 10X KlenTaq™ buffer (0.4 M Tricine-KOH, pH 9.2, 0.15 M KOAc, 35 mM Mg (OAc)₂ and 37.5 μ g/ml BSA). The annealing mixture was incubated at 95°C for 1 min and was gradually cooled at 5°C/min to annealing temperature (42°C unless specified). During the 5 min of incubation at the annealing temperature, the annealing mixture was supplemented with 5 μ l of a polymerase mixture consisting of 0.25 μ l Advantage cDNA polymerase mix™, 0.5 μ l 10 mM dNTPs and 0.5 μ l 10X KlenTaq™ buffer and incubated for 30 min at 68°C. Temperature was controlled using an MJ Minicycler™. Primary PCR was performed in a 25 μ l reaction consisting of 5 μ l of a second strand synthesis reaction mixture, 2.0 μ l 10X KlenTaq™ buffer, 200 μ M dNTPs, 5.0 pmole 3' gene specific primer (GSP), 10 pmole anchor primer and 0.25 μ l Advantage cDNA polymerase mix™. Basic PCR parameter, which varied depending on target size, were as follows: 95°C for 1 min, 27 cycles of amplification at 95°C for 30 sec, 58°C for 1

min and 68°C for a specified period (1 to 1.5 min per 1 kb target size), and 5 or 10 min further incubation at 68°C. For nested PCR, 0.5 µl of the primary PCR was used employing essentially the same PCR parameters. Nested PCR reactions (50 µl) contain 0.5 µl of primary PCR reaction mixture, 5 µl 10X KlenTaq™ buffer, 0.2 mM dNTPs, 10 pmole nested GSP, 10 pmole anchor primer and 0.5 µl Advantage cDNA polymerase mix™. A single primer reaction with GSP only or the anchor primer only is also performed with primary PCR reactions to distinguish C-ORF artifacts. PCR reactions are resolved in 1% agarose gels and bands are purified with a gel purification kit (Qiagen). Purified bands are directly sequenced with anchor primer and GSP.

C-ORF method for 3' cDNA end cloning: Reverse transcription is performed and the product is purified as described in the C-ORF method for 5' end cloning in the previous section except that 10 pmole of the T-SLAP reagent and 5 µg total RNA are used in place of the GSP. The primary PCR reaction mixture (50 µl) contains 2 µl of purified first strand cDNA, 5 µl 10X KlenTaq™ buffer, 0.2 mM dNTPs, 10 pmole GSP, 10 pmole anchor primer and 0.5 µl Advantage cDNA polymerase mix™. Nested PCR mixtures consist of the same components except 1 µl of a 10-fold diluted primary PCR of the first strand cDNA synthesis and substitution of nested GSP for GSP. PCR parameters including temperature and duration are the same as described in the previous section.

Northern and Southern blot hybridizations: RNA samples

separated in 2%-formaldehyde agarose gels were transferred to Nylon membranes. Northern blots were hybridized with ³²P-labeled mda-5 3' EST (0.4 kb) or a gel purified C-ORF product (1.8 kb) as previously described (2). A Southern blot was prepared by transferring the PCR samples resolved in a 1% agarose gel to the Nylon membrane after depurination and denaturation. The blot was hybridized with ³²P-labeled nested GSP (M5R4) (Table 1) in 50% formamide hybridization buffer at room temperature.

RESULTS AND DISCUSSION

The C-ORF method was designed to obviate the complicated and inefficient steps associated with the conventional RACE procedure, which includes TdT-mediated tailing or single strand oligonucleotide ligation by T4 RNA ligase (16-18, 36). Figure 1A provides a schematic representation of the C-ORF strategy in which a universal primer site is generated by annealing the D-SLAP reagent to reverse transcribed cDNA during second strand cDNA synthesis. The hairpin (D-SLAP) or clover-leaf (D-CLAP) structure (Figure 1B) which form bulky loop structures are hypothesized to prevent the degenerate sequences from annealing and extending in the middle of reverse transcribed cDNA because of steric hindrance. Several restriction sites (Spe I, Xho I, Hinc II) for cloning PCR products into vectors are included in this construct. To ensure formation of the D-SLAP structure prior to association with target cDNA, the length of the stem is made longer than the degenerate sequences (18 vs. 12

5

15

25

produced using all of the primer concentrations tested, with the exception of the 40 nM D-SLAP/0.4 μ M anchor primer combination. The most effective anchor primer combination in yielding a single specific amplification product employed
5 80 nM of D-SLAP/0.4 μ M anchor primer (Figure 2B, lane 5). The 1.8 kb *mda-5* C-ORF product labeled with 32 P was hybridized to a Northern blot of RNA from HO-1 human melanoma cells treated with recombinant human fibroblast interferon (IFN- β) and detected the same sized band with a
10 similar induction pattern as seen with the previously cloned *mda-5* EST (Figure 1D). Direct sequencing of gel purified products revealed a single ORF contiguous with the previously cloned *mda-5* fragment. When compared with the genomic sequence from a *mda-5* BAC genomic clone and primer
15 extension results, the cloned *mda-5* cDNA identified by C-ORF with the D-SLAP reagent terminated 61 bp downstream from the putative transcription start site (39). RT-PCR with 5' primers designed from the C-ORF derived *mda-5* sequence further verified the authenticity of the PCR product as the
20 complete ORF of *mda-5* (Figure 1E).

To confirm the utility of the C-ORF approach with the D-SLAP reagent for cloning the entire open reading frames from ESTs, studies were performed using three previously cloned
25 genes (ISG-56, 1.5 kb (27); *mda-9*, 2 kb (28)) and *mda-5* (3.6 kb). For comparison, standard RT-PCR was performed with each message with a 5' primer designed from a distal 5' sequence and a 3' primer used in nested PCR reactions with C-ORF. As shown in Figure 3A, each C-ORF reaction produced

0022143204260

a fragment of the predicted size. Although complex banding patterns were seen in the C-ORF reactions versus RT-PCR, distinguishing PCR artifacts was readily accomplished by simultaneously running an anchor-only PCR reaction without the requirement for Southern blot hybridization verification (15). C-ORF-derived PCR products of ISG-56 (1.5 kb) (27) and *mda-9* (2 kb) (28) contained the full ORF for these genes, but they lacked 34 nts (ISG-56) and 27 nts (*mda-9*), respectively, from the complete sequence reported in GenBank. The C-ORF approach with the D-SLAP reagent using *mda-5* sequence information generated 2 fragments, a 3 kb product that was identical to that obtained previously and a 1.2 kb fragment representing a prematurely terminated gene product (31). For practical purposes, to obtain the most sequence information and the complete ORF for a given EST, the larger sized fragment would be the optimal fragment to isolate and sequence when performing the C-ORF approach. The appropriate size of the cDNA can also be obtained by Northern blotting analysis using the EST as a probe.

The C-ORF approach with the D-SLAP reagent has been used successfully for obtaining the complete ORF for a number of additional genes. Applications of the C-ORF approach using the D-SLAP reagent with the prostate carcinoma tumor antigen-1 (PCTA-1) gene (29) has resulted in the identification of variants of this gene with sizes of 3.5, 3.2, and 3.0 kb. The C-ORF approach permitted an extension of the 5' UTR sequence reported for PCTA-1 (29) by 400 bp. Additionally, the C-ORF approach with the D-SLAP reagent was

used to determine the sequence of a cDNA associated with cellular senescence and terminal cell differentiation, OLD-35 (34). A number of novel ESTs have been identified using an approach called reciprocal subtraction differential RNA display (RSDD) (33). These include novel ESTs that display elevated expression as a function of cancer progression, called progression elevated genes (PEGen), or reduced expression during cancer progression, called progression suppressed genes (PSGen) (33). C-ORF with the D-SLAP reagent has been used to generate a complete open reading frame for PEGen 28 (1.6 kb), PEGen 42 (1.8 kb) and PSGen 12 (1.2 kb).

Although the reaction temperature of RT profoundly affects the efficiency of C-ORF for genes like *mda-5*, a high RT temperature is not mandatory for other C-ORF applications (RT can be performed at 42 to 45°C). RT temperature-dependence may be a consequence of extensive secondary structure at the 5' UTR of specific cDNAs (6). An initial application of the C-ORF approach for cloning OLD-35 produced a shorter than anticipated product where a strong hairpin structure is predicted (34). However, an additional round of C-ORF produced a full ORF of OLD-35. Numerous attempts to clone OLD-35 by conventional RACE only yielded a few hundred-bp PCR product and further extension using different primer sets was not possible. In general, increasing RT temperature should prove helpful in assuring first strand cDNA synthesis to the end of the transcript by overcoming secondary structure of the RNA (21). By using

RNase H-minus MMLV-RT (Superscript II), reverse transcription can be efficiently performed up to 48°C and even higher temperatures (55 to 65°C) can be achieved using commercially available thermostable RT (14,21).

5

Second strand cDNA synthesis appears to depend on the D-SLAP concentration with lower concentrations of the D-SLAP reagent being less effective in promoting second strand cDNA synthesis (Figure 2B lane 2 and 3). Additional experiments suggest that the concentration of the D-SLAP reagent should be higher than 20 nM. Combinations of different anchor-gene specific primer (GSP) concentration ratios in the primary PCR were also tested for ISG-56. Combinations of 0.2 or 0.4 μ M anchor plus 0.2 μ M GSP produced an appropriate sized PCR product. However, the yield of PCR product was generally higher when using concentrations of 0.4 μ M anchor and 0.2 μ M GSP. Since 0.4 pmole of the D-SLAP reagent (1/5 of the second strand cDNA synthesis reaction) is carried over to the primary PCR reaction and it contains anchor primer binding sites, it may be necessary to use additional anchor primers to obtain appropriate PCR amplification. Thus, it is possible that the inefficient second strand cDNA synthesis at low D-SLAP and high anchor primer concentrations can result in a high yield of non-specific PCR products in *mda-5* (Figure 1B, lane 3).

10
15
20
25

Parameters for D-SLAP reagent annealing during second strand cDNA synthesis, including annealing temperature, temperature ramping and single tube second strand cDNA synthesis

5

25

structure of the D-SLAP reagent prevents degenerate sequences from binding to internal sites as predicted, it is possible that the RT did not extend to the 5' end of the transcript. Alternatively, the D-SLAP reagent may bind to internal sites during second strand cDNA synthesis resulting in the generation of a shorter product. The 5' end of sequences of ten C-ORF products where the degenerate region of D-SLAP reagent primed are summarized in Table 2. Considering that the G/C content of the 12 bp 5' sequences are 71% on average or 100% for *mda-5* (31) and *mda-9* (28), respectively, it appears that the annealing of the D-SLAP reagent is not completely sequence-independent but rather prefers G/C rich regions. In fact, C-ORF PCR yields are higher for *mda-9* (28) than for ISG-56 (27), although the RT-PCR yields of the two products are similar. Furthermore, while ISG-56 (27) C-ORF largely depends on which second strand cDNA synthesis procedure is used, *mda-9* (28) is easily amplified by most of the protocols tested.

Current data suggests that the target sequence used in C-ORF is important, but it is not the most critical determinant for annealing of the D-SLAP reagent to target sequences. Sequence analysis of 12 bp stretches in *mda-9* reveals one G/C site of 12/12, one G/C site of 11/12, one G/C site of 10/12 and three G/C sites of 9/12 (28). The C-ORF product of *mda-9* begins at the highest G/C content site that is located 27 bp downstream of the reported cDNA end of this cDNA. Although the D-SLAP reagent annealed to the highest G/C rich site in *mda-9*, based on the sequence analysis of

annealing sites (Table 2) this primer could also have annealed to other sites with > 75% G/C content in *mda-9*. In contrast, the D-SLAP reagent annealed to ISG-56 at the 58.3% G/C content site, whereas ISG-56 has two 12 bp stretches of 10/12 G/C and 6 sites of 9/12 G/C, respectively (27). If the G/C sequence content were the primary determinant of D-SLAP annealing and assuming a preference bias of PCR for shorter fragments, C-ORF applied to ISG-56 would be predicted to generate a mixture of products including the annealing site containing the 58.3% G/C content. The D-SLAP reagent could potentially anneal to all of the G/C rich sites, but the C-ORF product of ISG-56 that was amplified by PCR derived from a site of lower G/C content (58.3%) than the average G/C content of D-SLAP annealing sites (71%).

The propensity of C-ORF to generate near-end products may result either from preferential second strand cDNA synthesis when the D-SLAP reagent is annealed at the 3' end of the first strand cDNA or from an unanticipated PCR bias for the annealed D-SLAP reagent. In either case, the stem-and-loop structure of D-SLAP certainly plays a significant role in the preferential production of near-end fragments when using the C-ORF method. This bias may result by structurally preventing efficient second strand cDNA synthesis from deep internal sites within the cDNA. By providing a rigid stem-and-loop structure at the annealing temperature, it is possible that the longer stretch of DNA in the displaced strand that results from D-SLAP annealing has a greater chance to interfere with second strand cDNA synthesis. This

002277 2204260

may occur either by forming a complex secondary structure or by an undefined interaction of the displaced DNA strand with the D-SLAP reagent.

5 It is assumed that the stem-and-loop structure of D-SLAP facilitates second strand cDNA synthesis from the end or near the end of the cDNA. In this context, degenerate clover-leaf annealing primers (D-CLAP), containing three stem-and-loop structures, might even be more effective than
10 the D-SLAP reagent in inhibiting second strand cDNA synthesis from internal priming sites, thereby alleviating the G/C sequence-dependence of D-SLAP. It is also established that RT has TdT-like activity and can add multiple Cs at the 3' end of the first strand cDNA from
15 capped RNA (10,11). Based on these considerations, we designed two D-CLAP reagent, D-CLAP1 and D-CLAP2. While the D-CLAP1 reagent contains an annealing site with the sequence GGGN₁₀, the D-CLAP2 reagent contains 13 random oligonucleotides. C-ORF with the D-CLAP1 and D-CLAP2
20 reagents was performed with ISG-56 (27), *mda-9* (28), *mda-5*, PCTA-1 from either poly A site (3.5 and 5 kb, respectively (29, 39) and fibronectin (8 kb) (30). A single round of the C-ORF approach performed with the D-CLAP1 reagent generated
25 bands of the expected size, not only for shorter transcripts (ISG-56 and *mda-9*) but also for larger transcripts (PCTA-1/pA and fibronectin) (Figure 4A), although this approach did increase band complexity. The annealing site sequence of ISG-56 is further upstream of the C-ORF product performed using the D-SLAP reagent, but it is still shorter than the

00227 2204260

reported gene sequence by 11 nts (27). In contrast, the C-ORF derived fragment of PCTA-1 obtained using the D-CLAP1 reagent is shorter than that obtained using the D-SLAP reagent, but it is longer than the reported sequence (29, 39). Although C-ORF with the D-CLAP1 reagent successfully supports cDNA cloning up to 8-kb transcript size (close to the limit of PCR), as expected it appears not to anneal to the CCC-tail generated by RT-TdT like activity (10, 11).

10 The full protein coding region of ISG-56 (27), *mda-9* (28),
mda-5 (31), PCTA-1 (3.5 kb and 5 kb) (29, 39) and
fibronectin (30) could also be amplified using the C-ORF
approach with the D-CLAP2 reagent (random 13 bp annealing
site, Figure 4B). Compared with the C-ORF approach using
15 the D-CLAP1 reagent, the D-CLAP2 reagent clearly reduced
band complexity, although in general it generated shorter
sized fragments (43 bp short in PCTA-1). With increasing
target size, the complexity of the PCR generated products
increased when performing C-ORF with either the D-CLAP1 or
20 D-CLAP2 reagent. The increased band complexity obtained
when using C-ORF with long cDNA targets may occur because
the RT pre-termination (6) and internal priming sites
overcome the steric interference of the stem-and-loop
structure of the D-CLAP reagents. C-ORF with the D-CLAP1
25 reagent seems to be more dependent on target sequence than
C-ORF with the D-CLAP2 reagent since the GGG sequence
stretch upstream of the random sequence in the D-CLAP1
reagent can more strongly direct primer annealing and
subsequent extension than the D-CLAP2 reagent. Attempts to

003377" 02042259

directly sequence the D-CLAP1 reagent C-ORF product with the anchor primer were unsuccessful, probably because of the hairpin structure in the anchor primer and the heterogeneous annealing of the GGG stretch, e.g., GGG can anneal in either direction to CCCC or CCCC. Provided that C-ORF with the D-CLAP2 reagent can yield the full protein coding region as exemplified in a number of applications, C-ORF using the D-CLAP2 reagent would be preferable to performing C-ORF with the D-CLAP1 reagent.

The utility of the D-SLAP reagent and C-ORF in cloning the 3' end of a cDNA was investigated to determine if this method could be used to obtain a complete 3' UTR of the PCTA-1 cDNA (29). An oligo dT stem and loop annealing primer (T-SLAP) was made by replacing oligo-dT for the random sequence of the D-SLAP reagent and was included in an RT reaction during the C-ORF procedure. PCR amplification (primary and nested) resulted in a specific 1.2-kb fragment, which was confirmed by genomic sequence and RT-PCR as PCTA-1 (Figure 5). The same protocol was also applied to 3' end cloning of OLD-35 (34), PEGen 28 and PEGen 50 (33) resulting in a 0.5 to 1 kb PCR amplification product corresponding to the 3' region of these cDNAs. These results indicate that primers based on a stem-and-loop structure can be efficiently used for both 5' and 3' end cloning of cDNAs.

Although the C-ORF method employs a common strategy involving a single side specific PCR reaction that is also used in the conventional RACE approach (14), C-ORF is unique

5
10
15
20
25

in 9 out of 10 test cases. Targets as small as 0.3 kb and as large as 8 kb could be amplified by the C-ORF protocol in a single reaction. These results confirm that the C-ORF approach will have wide applicability for identifying the complete protein coding regions of most ESTs and in many cases this will be achieved by a single application of the C-ORF methodology.

Applications of the C-ORF approach for cloning the complete open reading frame of diverse genes demonstrates that this approach is an efficient and simple way of cloning both 3' and 5' ends of cDNAs from EST sequences. With a small amount of starting material (1/5 to 1/3 of an RT reaction with 2 μ g of total RNA), C-ORF efficiently amplifies the complete protein coding region of diverse genes in most cases without the need for repetitive applications. Although in its present form C-ORF does not appear applicable for identifying the transcription start site, C-ORF is a cost-, time- and laborsaving method over currently used methods such as library screening and RACE for quickly obtaining biologically meaningful sequence data produced by C-ORF permits a determination of the uniqueness of the reported ESTs and provides sufficient information to procure corresponding clones from various providers to rapidly determine the full-length sequence of the gene. The quickness, ease of performance and efficiency of the C-ORF approach enables one to pursue multiple cDNA cloning projects simultaneously, which is necessary to expedite ongoing genome projects.

00227 8204260
5 Additionally, since D-SLAP or D-CLAP primers anneal to random sequence and provide primer sites, the primers can also be used for genomic cloning or cloning cDNA of a family of genes in case that partial sequence of the target
10 fragment is known. Furthermore, the structural motif of D-SLAP or D-CLAP potentially inhibits transcription and/or translation if specific sequence in substitution of random sequence for a target molecule is designed to anneal to the molecule in reverse orientation. In case, D-SLAP or D-CLAP
15 primer can be used for blocking function of specific gene and can be an alternative way of gene therapy. Also, if the bulky structure of D-SLAP or D-CLAP is antigenic enough to raise antibody, specific sequence in substitution of random sequence can be useful for sequence-specific capture of nucleic acids.

20 In conclusion, C-ORF with its simplicity, versatility and long-range capability can significantly contribute to genome discovery efforts by overcoming the rate limiting full length cDNA cloning step required for defining and functionally evaluating the numerous ESTs and incomplete cDNAs that continue to be identified.

Table 1. Sequence of gene specific primers used in the C-ORF cloning technology.

Primer	Gene	Sequence
AP-1	D-SLAP	5' TTCTGGTCGACTAGTGTTAAGCTCGAGAC 3'
AP-2	D-CLAP	5' CACGATCAGTCGACGAAGTCGACACTCGAG 3'
M5R1	mda-5	5' TTTT TTTT TTTT TTTT CAGAGTAAACAATC 3'
M5R2	mda-5	5' TGTGCACCATCATTTGTCCTCCCAAGCC 3'
M5R3	mda-5	5' AATCTGACATTGGACTCATTTGAC 3'
M5R4	mda-5	5' GTTTGAATCCTTGTCTATTATTCTAG 3'
M5S1	mda-5	5' GCCTGAGAGCCCTGTGGACAACCTCG 3'
56R1	ISG-56	5' GTGGCTGATATCTGGGTGCCCTAAGG 3'
56R2	ISG-56	5' CCTAAGGACCTTGTCTCACAGAGTTC 3'
56S1	ISG-56	5' CCAGATCTCAGAGGAGCCCTGGCTAAGC 3'
M9R1	mda-9	5' AATCAGGATAAAGTGTCAACTATC 3'
M9R2	mda-9	5' ATCCCCAAGTAGCTAGGTACATAATC 3'
M9S1	mda-9	5' CCTCAGAAGTCCGTGCCAGTGACCGG 3'
Fnr1	fibronectin	5' TTTT TTTT TTTT TTTT TGTGGAATGTAATC 3'
Fnr2	fibronectin	5' AGATGGATCTTGGCAGAGAGACATGC 3'
PCTAR1	PCTA-1	5' GAAGAAGTAGAACATCAGTGCC 3'
PCTAR2	PCTA-1	5' TCTTCTGTACAGCAGTATCTTACAT 3'
PCTAR3	PCTA-1	5' TTTT TTTT TTTT TTTT TTTTGTGTCATGCGG 3'
PCTAR4	PCTA-1	5' TTACAAAACAGCTCCCCAAATGGTGAAACT 3'

Table 2. Sequence of the 5' end of the C-ORF products.

5

- 10

15

20

25

5 32. Loh, E.Y., Elliot, J.F., Cwirla, S., Lanier, L.L., and
Davis, M.M. Polymerase chain reaction with single-sided
specificity: analysis of T cell receptor delta chain,
Science. 243: 217-220, 1989.

33. Troutt, A.B., McHeyzer-Williams, M.G., Pulendran, B.,
10 and Nossal, G.J. Ligation-anchored PCR: a simple
amplification technique with single-sided specificity,
Proc Natl Acad Sci U S A. 89: 9823-9825, 1992.

34. Edwards, J.B., Delort, J., and Mallet, J.
Oligodeoxyribonucleotide ligation to single-standed
15 cDNAs: a new tool for cloning 5' ends of mRNA and for
constructing cDNA libraries by in vitro amplification,
Nucleic Acids Res. 19: 5227-5232, 1991.

35. Liu, X. And Gorovsky, M.A. Mapping the 5' and 3' ends
of Tetrahymena thermophila mRNAs using RNA ligase
20 mediated amplification of cDNA ends (RLM-RACE), Nucleic
Acids Res. 21: 4954-4960, 1993.

36. Frohman, M. RACE: Rapid Amplification of cDNA Ends. In:
M. Innis, D. Gelfand, J. Sninsky, and T. White (eds.),
PCR Protocols, pp. 28-38. San Diego, CA: Academic
25 Press, 1990.

37. Carninci, P., Nishiyama, Y., Westover, A., Itoh, M.,
Nagaoka, S., Sasaki, N., Okazaki, Y., Muramatsu, M.,
and Hayashizaki, Y. Thermostabilization and
thermoactivation of thermolabile enzymes by trehalose

and its application for the synthesis of full length cDNA, Proc Natl Acad Sci U S A. 95: 520-524, 1998.

38. Rychlik, W. In: B. White (ed.) Methods in Molecular Biology, Vol. 15, pp. 31-40. Totowa, NJ: Humana Press, 1993.
39. Chenchik, A., Diachenko, L., Mogadam, F., Tarabykin, V., Lukyanov, S., and Siebert, P.D. Full-length cDNA cloning and determination of mRNA 5' and 3' ends by amplification of adaptor-ligated cDNA, Biotechniques. 21: 526-534, 1996.
40. Maunders, M. DNA and RNA ligases. In: M. Burrell (ed.) Methods of Molecular Biology. Enzymes of Molecular Biology, Vol. 16, pp. 213-230. Totowa, NJ: Humana Press, 1993.
41. Maruyama, K. And Sugano, S. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides, Gene. 138: 171-174, 1994.
42. Fromont-Racine, m., Bertrand, E., Pictet, R., and Grange, T. A highly sensitive method for mapping the 5' termini of mRNAs, Nucleic Acids Res. 21: 1683-1684, 1993.
43. Wathelet, M., Moutschen, S., Defilippi, P., Cravador, A., Collet, M., Huez, G., and Content, J. Molecular cloning, full-length sequence and preliminary characterization of a 56-kDa protein induced by human interferons, Eur J Biochem. 155: 11-17, 1986.
44. Lin, J.J., Jiang, H., and Fisher, P.B. Melanoma differentiation associated gene-9, mda-9, is a human gamma interferon responsive gene, Gene. 207: 105-110,

15

52. Frohman, M.A. Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE, *Methods Enzymol.* 218: 340-356, 1993.
53. Chencik, A., Diachenko, L., Chang, C., and Kuchibhatla, S. Great lengths cDNA synthesis kit for high yields of full-length cDNA, *CLONTECHniques.* 9: 9-12, 1994.
54. Kellogg, D.E., Rybalkin, I., Chen, S., Mukhamedova, N., Vlasik, T., Siebert, P.D., and Chenchik, A. TaqStart Antibody: "hot start" PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase, *Biotechniques.* 16: 1134-1137, 1994.
55. Gopalkrishnan, R.V. and Fisher, P.B. Unpublished results, 1999.

5

- A) admixing

- 10

- 15

- 20

- 25

5

5

5

5

10

10

15

15

15

15

25

25

3. The method of claim 1, wherein the first primer has
the sequence
3'-
NNNNNNNNNNNNNCAGAGCTCAAATTTGTGATCAGCTGGTCTTTCACAAATTTGAGCTC
TG-5' (D-SLAP).

4. The method of claim 1, wherein the first primer has
the sequence
3'NNNNNNNNNNNGGAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGTAGAAT
ACATCTTGAGCTAT-5' (D-CLAP1).

5. The method of claim 1, wherein the first primer has
the sequence
3'NNNNNNNNNNNNNNAGAGCTCACAGCTGAAGCAGCTGACTAGCACCTAGTGT
AGAATACATCTTGAGCTAT (D-CLAP2).

6. The method of claim 1, wherein the first primer
comprises an inosine nucleotide.

7. The method of claim 1, wherein the loop structure is a
simple loop structure, or a cloverleaf loop structure.

8. A method for generating a cDNA library which comprises:

A) admixing

5

10

15

20

25

(iii) a polymerase;

B) incubating the mixture from step (A) under suitable conditions for DNA synthesis by the polymerase; and

C) performing a polymerase chain reaction by admixing

(i) an aliquot of the mixture from (B),

5 (ii) a second primer which has the identical sequence
as the defined nucleotide sequence of the primer
in (A)(i),

(iii) a third primer which comprises

10

(a) a fifth sequence identical to the third
sequence of the first primer, linked to

15

(b) a sixth sequence identical to a portion
of the second sequence of the first
primer, and

(iv) a polymerase

20 under conditions suitable for a polymerase chain reaction so
as to produce double-stranded cDNA reaction products thereby
generating a cDNA library.

9. The method of claim 8, wherein the single-stranded DNA
25 is a cDNA reverse transcribed from an mRNA.

10. The method of claim 8, wherein the first primer has
the sequence 3'-
NNNNNNNNNNNNNCAGAGCTCAAATTTGTGATCAGCTGGTCTTTCACAAATTTG

11. The method of claim 8, wherein the first primer has the sequence

10

15

20

25

(i) a first primer capable of forming a stem-loop structure, comprising

(a) at the 3' end of the primer, a first random sequence linked to

(b) a second sequence, linked to

(c) a third sequence which forms a loop

structure, linked to

- 5 (d) a fourth sequence, at the 5' end of the first primer, which is complementary to the second sequence, and

(ii) a second primer which comprises

- 10 (a) a fifth sequence identical to the third sequence of the first primer, linked to
(b) a sixth sequence identical to a portion of the second sequence of the first primer.

- 15 16. A method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises:

(a) admixing

- 20 (i) a biological sample containing mRNA,

(ii) a primer which forms a stem-loop structure, comprising:

- 25 (a) a poly-T sequence at the 3' end of the primer linked to

(b) a first random sequence linked to

(c) a second sequence which forms a loop

5

10

15

20

25


Method for Full-Length cDNA Cloning Using Degenerate Stem-
Loop Annealing Primers

Abstract of the Disclosure


5 The present invention provides a method for isolating a
double-stranded cDNA having a nucleotide sequence of a
complete open reading frame which comprises: (A) admixing
(i) an isolated single-stranded cDNA, (ii) a first primer
capable of forming a stem-loop structure, comprising (a) at
10 the 3' end of the primer, a first random sequence, linked to
(b) a second sequence, linked to (c) a third sequence which
forms a loop structure, linked to (d) a fourth sequence, at
the 5' end of the first primer, which is complementary to
the second sequence, under hybridization conditions
15 sufficient for annealing the first sequence of the first
primer to the sequence at the 3' end of the single-stranded
cDNA, and (iii) a polymerase; (B) incubating the mixture
from step (A) under suitable conditions for DNA synthesis;
and (C) performing a polymerase chain reaction by admixing
20 (i) an aliquot of the mixture from (B), (ii) a second primer
which specifically binds to the single-stranded cDNA, (iii) a
third primer which comprises (a) a fifth sequence identical
to the third sequence of the first primer, linked to (b) a
sixth sequence identical to a portion of the second sequence
25 of the first primer, and (iv) a polymerase, under conditions
suitable for a polymerase chain reaction so as to produce a
double-stranded cDNA reaction product, thereby isolating the
cDNA having the sequence of the complete open reading frame.

003317 3204260


Figure 1A



B.




Figures 2A, 2B, and 2C




Figures 2D and 2E

D.




Lane 1- ctl with EST
Lane 2- IFN- β with EST
Lane 3- ctl with C-ORF product
Lane 4- IFN- β with C-ORF product

E.




Lane 1- 1 kb ladder
Lane 2- RT-PCR R2/S8
Lane 3- RT-PCR R4/S8

Figure 3




Figures 4A and 4B

A.




Lane 1 & 6- 1 kb ladder
 Lane 2- mda-9
 Lane 3- fibronectin
 Lane 4- PCTA-1 (R1)
 Lane 5- PCTA-1 (pA)
 Lane 7- mda-5
 Lane 8- ISG-56

B.



Lane 1- 1 kb ladder
 Lane 2- fibronectin
 Lane 3- PCTA-1 (pA)
 Lane 4- mda-9
 Lane 5- ISG 56

Figure 5

Lane 1- 1 kb ladder

Lane 2- AP only

Lane 3- GSP/AP

Lane 4- GSP only

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**METHOD FOR FULL-LENGTH cDNA CLONING USING DEGENERATE STEM-LOOP
ANNEALING PRIMERS**

the specification of which:
(check one)

☒ is attached hereto
☐ was filed on _____ as
 Application Serial No _____
 and was amended _____
 (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 (a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International Application which designated at least one country other than the United States, listed below. I have also identified below any foreign application for patent or inventor's certificate, or PCT International Application having a filing date before that of the earliest application from which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

<u>Number</u>	<u>Country</u>	<u>Filing Date</u>	<u>Yes</u>	<u>No</u>
N/A				

002422-1 8204260

Applicants: Paul B. Fisher and Dong-chul Kang

U.S. Serial No.: Not Yet Known

Filed: Herewith

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Applicants: Paul B. Fisher and Dong-chul Kang

U.S. Serial No.: Not Yet Known

Filed: Herewith

Declaration and Power of Attorney

Page 3

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White _____ Reg No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor _____ Paul B. Fisher

Inventor's signature _____

Citizenship United States of America Date of signature _____

Residence 15 Gordon Place, Scarsdale, New York 10563, USA

Post Office Address same as above

Full name of joint inventor (if any) _____ Dong-chul Kang

Inventor's signature _____

Citizenship Korea Date of signature _____

Residence 200 Union Avenue, Apartment A, Rutherford, New Jersey 07070 USA

Post Office Address same as above

Full name of joint inventor (if any) _____

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

002211 2204260